<DOC>
	<DOCNO>NCT00413101</DOCNO>
	<brief_summary>This single arm study determine effect complete anemia correction anemic patient end-stage renal disease currently receive suboptimal dos NeoRecormon . Patients dialysis receive NeoRecormon , hemoglobin level &lt; 105g/L , treat subcutaneous NeoRecormon dose determine investigator order reach ( within 3 month ) maintain hemoglobin level range 120-135g/L . Heart function quality life measure anemia correction . The anticipated time study treatment 3-12 month , target sample size 100 individual .</brief_summary>
	<brief_title>A Study NeoRecormon ( Epoetin Beta ) Patients With End Stage Renal Disease .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , 1875 year age ; endstage renal disease ; renal dialysis &gt; = 3 month ; receive NeoRecormon treatment &gt; = 3 month ; Hb stable &lt; 105g/L , LVMI &gt; 160g/m2 . unstable hypertension , myocardial infarction , unstable angina pectoris risk deep vein thrombosis last 6 month ; use ESA NeoRecormon ; acute infection ; use iv NeoRecormon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>